Treats mild to moderate dementia of the Alzheimer’s type. ANDA 77604, held by Yabao Pharm. Galantamine Hydrobromide.
As of Nov 15, 2026, ANDA 77604 (Galantamine Hydrobromide), held by Yabao Pharm, was first approved by FDA on Feb 6, 2009, with 3 approved supplements and 0 published complete response letters.
Galantamine tablets are indicated for the treatment of mild to moderate dementia of the Alzheimer’s type.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 6, 2009 | Original application | Approved | None posted |
| Galantamine HydrobromideEQ 4MG BASE · tablet;oral | Galantamine Hydrobromide | Rx |
| Galantamine HydrobromideEQ 8MG BASE · tablet;oral | Galantamine Hydrobromide | Rx |
| Galantamine HydrobromideEQ 12MG BASE · tablet;oral | Galantamine Hydrobromide | Rx |
| Jun 28, 2023 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jun 28, 2023 | Supplement 3Labeling · Standard review | Approved | None posted |
| Dec 27, 2017 | Supplement 2Labeling · Standard review | Approved | None posted |
| Feb 6, 2009 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters